Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30649033 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| SCHEMBL14887010 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| SCHEMBL4682693 | 0.95 | FDFT1 (0.91) | FDFT1 | |
| SCHEMBL16116566 | 0.94 | FDFT1 (0.90) | FDFT1 | |
| SCHEMBL4105356 | 0.94 | FDFT1 (0.90) | FDFT1 | |
| Lapaquistat Acetate SCHEMBL206424 | 0.93 | FDFT1 (1.00) | FDFT1 | |
| Lapaquistat Acetate SCHEMBL8007641 | 0.93 | FDFT1 (1.00) | FDFT1 | |
| Lapaquistat Acetate SCHEMBL29395209 | 0.93 | FDFT1 (1.00) | FDFT1 | |
| Lapaquistat Acetate SCHEMBL12882274 | 0.93 | FDFT1 (1.00) | FDFT1 | |
| Lapaquistat Acetate SCHEMBL29379346 | 0.93 | FDFT1 (1.00) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124215-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | THE FRANCIS CRICK INST LIMITED (GB) | 2026-05-07 | — | — | US | claimed |
| EP-4659812-A1 | DETECTION METHODS AND COMBINATION THERAPIES OF CELLS WITH EXTRACELLULAR RAS EXPRESSION | Bumm, Thomas (DE) | 2025-12-10 | — | — | EP | claimed |
| EP-4598518-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | The Francis Crick Institute Limited (GB) | 2025-08-13 | — | — | EP | claimed |
| WO-2024074554-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2024-04-11 | — | — | WO | claimed |
| CN-116744934-A | Inhaled statins for the treatment of viral respiratory diseases | 加利福尼亚大学董事会 | 2023-09-12 | — | — | CN | claimed |
| US-20230172849-A1 | INHALED STATINS FOR TREATMENT OF VIRAL RESPIRATORY DISEASES | UNIV CALIFORNIA (US) | 2023-06-08 | — | — | US | claimed |
| EP-4146340-A1 | INHALED STATINS FOR TREATMENT OF VIRAL RESPIRATORY DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-15 | — | — | EP | claimed |
| WO-2021226479-A1 | INHALED STATINS FOR TREATMENT OF VIRAL RESPIRATORY DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-11 | — | — | WO | claimed |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | claimed |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | ACORDA THERAPEUTICS, INC. | 2020-05-21 | — | — | US | claimed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | claimed |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-05 | — | — | US | claimed |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-15 | — | — | US | claimed |
| US-20060241096-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | SUGIYAMA YASUO | 2006-10-26 | — | — | US | claimed |
| US-20060052362-A1 | Skeletal muscle protecting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | claimed |
| EP-1600166-A1 | SKELETAL MUSCLE PROTECTING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-11-30 | — | — | EP | claimed |
| US-20040204500-A1 | Preventives/remedies for organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-10-14 | — | — | US | claimed |
| EP-1407782-A1 | PREVENTIVES/REMEDIES FOR ORGAN FUNCTIONAL DISORDERS AND ORGAN DYSFUNCTION | Takeda Chemical Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | claimed |
| EP-0862562-B1 | BENZOXAZEPINE COMPOUNDS, THEIR PRODUCTION AND USE AS LIPID LOWERING AGENTS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-07-04 | — | — | EP | claimed |
| US-6110909-A | SQUALENE SYNTHETASE INHIBITING ANTILIPEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124215-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | FDFT1, FNTA, FNTB | FDFT1 1/4885 |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885 |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | FDFT1 4716/4885 |
| US-20040204500-A1 | Preventives/remedies for organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885 |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | FDFT1 4716/4885 |
| US-20090118255-A1 | Crp Lowering Agent | SPR, RBP1, HMGCR | FDFT1 7/4885 |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | SQLE, DHPS, COASY | FDFT1 13/4885 |
| US-20060052362-A1 | Skeletal muscle protecting agent | GYS1, CPT1B, TNNC1 | FDFT1 8/4885 |
| US-20060241096-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.